慢性病患者的心脏器械治疗:最新情况
Bogdan Caba1,2, Laura Vasiliu1,2, Maria Alexandra Covic1
1Faculty of Medicine, "Grigore T. Popa" University of Medicine, 700115 Iasi, Romania.
Journal of clinical medicine
|January 23, 2024
概括
心血管疾病和慢性病 (CKD) 分享风险. 在CKD患者中,心脏器械治疗对心力衰竭和死亡率有好处,但感染风险更高.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 心血管疾病 (CVD) 和慢性病 (CKD) 密切相关,增加不良事件的风险.
- 慢性病患者经历了较高的心律失常负担,这影响了对心脏器械治疗的决策.
- 目前关于心脏器械治疗慢性病患者的数据有限,主要来自观察性研究和病例报告.
研究的目的:
- 审查慢性病患者心脏器械治疗的现有证据.
- 评估心脏再同步治疗 (CRT) 和植入式心脏转移器除器 (ICD) 在CKD患者的疗效和安全性.
- 突出心脏器械植入在CKD患者群体中的具体考虑和挑战.
主要方法:
- 对观察性研究和病例报告的文献综述,重点关注接受心脏器械治疗的CKD患者.
- 对CRT,ICD和CRT-D对死亡率,心力衰竭症状,功能和感染的影响数据的分析.
- 检查透析患者心脏节奏调节的增加需求.
主要成果:
- 心脏再同步治疗 (CRT) 与降低死亡率,改善心力衰竭症状,以及在早期CKD阶段改善功能有关.
- 植入式心脏转移器除器 (ICD) 显著降低了CKD患者的死亡率,用于预防心脏突然死亡的二次预防.
- 对于符合条件的患者,建议使用除器 (CRT-D) 进行心脏再同步治疗. 透析患者对节拍的需求增加了三倍. 慢性病是心脏器件感染的独立风险因素.
结论:
- 心脏器械治疗在CKD患者的心血管结果方面提供了显著的好处,尽管感染风险增加.
- 仔细的患者选择和监测对于优化心脏器械治疗在患有CKD的人的结果至关重要.
- 需要进一步的研究,以确定心脏器件植入和管理在多样化的CKD人口的最终指南.
相关概念视频
01:27Dialysis
319
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
319
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:11Renal Failure: Dose Adjustments
92
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
92
01:17Factors Affecting Renal Clearance: Renal Impairment
95
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
95
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167